title: [Tgammadelta lymphocytes in oncology: unconventional killer lymphocytes].
abstract: Gamma delta T cells are a distinct subset of CD3+ T cells featuring both T cells receptors that are encoded by Vgamma- and Vdelta- gene segments and characteristics of innate immunity. In human blood, 80% of those express Vgamma9Vdelta2-TCRs that are specific for conserved non peptidic compound, phosphoantigens (PAgs). Vgamma9Vdelta2 T cells recognize in vitro a wide array of transformed cells and are activated in vivo in various tumor. Owing to their ability to directly kill tumor cells and produce inflammatory cytokines (such as IFN-gamma) boosting antitumor properties of other immune effector cells, gamma delta T cells contribute to protective immunity against cancers. These observations, and the recent availability of synthetic clinical grade PAg or pharmacological inducers of PAg (e.g. aminobisphosphonates) able to trigger Vgamma9Vdelta2 T cell, have fostered development of new gammadelta T cell-based therapeutic strategies, which are depicted in this review.
authors.affiliation: EE 341 Biothérapies innovantes, Université de Rennes 1, Faculté de médecine de Rennes, Rennes Cedex 35043, France. veronique.catros@ univ-rennes1.fr
authors.forename: Véronique
authors.initials: V
authors.lastname: Catros
authors.forename: Olivier
authors.initials: O
authors.lastname: Toutirais
authors.forename: Françoise
authors.initials: F
authors.lastname: Bouet
authors.forename: Florian
authors.initials: F
authors.lastname: Cabillic
authors.forename: Mireille
authors.initials: M
authors.lastname: Desille
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Fournié
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm / Q000737:chemistry / Q000276:immunology; D002986:Clinical Trials as Topic; D003602:Cytotoxicity, Immunologic; D003713:Dendritic Cells / Q000276:immunology; D004164:Diphosphonates / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D007113:Immunity, Innate; D054992:Immunological Synapses; D007167:Immunotherapy / Q000379:methods; D016219:Immunotherapy, Adoptive; D008213:Lymphocyte Activation; D008798:Mevalonic Acid / Q000378:metabolism; D051379:Mice; D009363:Neoplasm Proteins / Q000737:chemistry / Q000276:immunology; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy; D010750:Phosphoproteins / Q000276:immunology; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000032:analysis*; D016176:T-Lymphocyte Subsets / Q000276:immunology*
chemical_list: D000951:Antigens, Neoplasm; D004164:Diphosphonates; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D009363:Neoplasm Proteins; D010750:Phosphoproteins; D016692:Receptors, Antigen, T-Cell, gamma-delta; D008798:Mevalonic Acid